Then there was the time Robert Ward, the CEO of Radius Health, spoke with Cramer and confirmed that one of its drugs seemed to be causing a solid reduction in broken bones, which can be a life or death issue for the elderly.  Sure enough, on Thursday investors learned that Radius' clinical trial showed a dramatic reduction in broken bones. And while the stock was up 15 percent on Thursday, it is up 56 percent since that interview alone.  But the stock that really had Cramer confused was Allergan. How could that stock have failed to rise based on its very smart bid for Kythera Biopharmaceuticals?  Kythera is the maker of the injectable drug that works to combat double chins. Allergan already dominates the market to offer Botox to dermatologists all over the country, so it seemed like a no-brainer for Cramer that Allergan's salespeople could easily add Kythera's drug into the mix when they make the rounds for Botox.  ---------------------------------------------------------- Read more from Mad Money with Jim Cramer Cramer Remix: You smarter than Janet Yellen? Cramer: One smokin' hot dangerous IPO Cramer on the Fed: The good & bad news ----------------------------------------------------------  "I couldn't believe that people failed to realize how additive Kythera will be to the toolkit of the Allergan detail person," Cramer said.  But most importantly, when looking back at all of these CEO interviews, Cramer saw a pattern. A pattern that revealed that all of these gains are attainable for your portfolio, but require a specialized skill: Listen to the CEOs!  The CEOs are not wasting your time, Cramer's time or their own time. They are helping investors to learn about their products so you can make money—it's that easy.
Jim Cramer has noticed a pattern with biotech stocks, and you could easily use this method for your portfolio.